48 results
8-K
EX-99.2
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
a Potential Best-In-Class Antibody Targeting Toxic Amyloid Beta Oligomers (AβOs) for Early Alzheimer’s Disease (AD) Large market in need of additional … treatment options Sabirnetug (ACU193): monoclonal antibody (mAb) highly selective for toxic AβOs Experienced leadership team with extensive AD drug
8-K
EX-99.1
ABOS
Acumen Pharmaceuticals Inc
14 May 24
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
7:35am
biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD … oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed
8-K
EX-99.1
c48lgh03aw60b3 6ku9
26 Mar 24
Results of Operations and Financial Condition
7:42am
8-K
EX-99.1
25hf9okb0i 5mgav0vb
19 Mar 24
Corporate Presentation March 2024 1
8:05am
8-K
EX-99.1
5pyg b6i814q5
1 Feb 24
Departure of Directors or Certain Officers
7:16am
8-K
EX-99.1
swf qp2hredggzw5
12 Jan 24
Corporate Presentation January 2024 1
8:42am
8-K
EX-99.1
i44li2m75qjagxv
8 Jan 24
Regulation FD Disclosure
8:33am
8-K
EX-99.1
u4hd1r8d1yuxbq8xod8
4 Dec 23
Corporate Presentation December 2023 1
7:45am
8-K
EX-99.1
t7rgwdp1jxcb7f8g4zge
13 Nov 23
Corporate Presentation November 2023 1
5:10pm
8-K
EX-99.1
uz7vwgr7jyv19d 7x
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.2
n4oflsh9q
13 Nov 23
Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
7:20am
8-K
EX-99.2
8k8jrn4r5zt1k4a66d5
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
8-K
EX-99.1
e8uh12qh qn
8 Aug 23
Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights
7:33am
424B5
warx127
20 Jul 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-1.1
0t77i3bgkwuf
20 Jul 23
Entry into a Material Definitive Agreement
4:06pm
424B5
3sabak7ih0usio
17 Jul 23
Prospectus supplement for primary offering
4:49pm
8-K
hjfblp
17 Jul 23
Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human
6:06am